Literature DB >> 20440276

Role of triglyceride-rich lipoproteins in diabetic nephropathy.

John C Rutledge1, Kit F Ng, Hnin H Aung, Dennis W Wilson.   

Abstract

Diabetic nephropathy is an increasingly important cause of morbidity and mortality worldwide. A large body of evidence suggests that dyslipidemia has an important role in the progression of kidney disease in patients with diabetes. Lipids may induce renal injury by stimulating TGF-beta, thereby inducing the production of reactive oxygen species and causing damage to the glomeruli and glomerular glycocalyx. Findings from basic and clinical studies strongly suggest that excess amounts of a variety of lipoproteins and lipids worsens diabetes-associated microvascular and macrovascular disease, increases glomerular injury, increases tubulointerstitial fibrosis, and accelerates the progression of diabetic nephropathy. The increasing prevalence of obesity, type 2 diabetes mellitus, and diabetic nephropathy means that interventions that can interrupt the pathophysiological cascade of events induced by lipoproteins and lipids could enable major life and cost savings. This Review discusses the structural, cellular, and microscopic findings associated with diabetic nephropathy and the influence of lipoproteins, specifically triglyceride-rich lipoproteins (TGRLs), on the development and perpetuation of diabetic nephropathy. Some of the accepted and hypothesized mechanisms of renal injury relating to TGRLs are also described.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20440276     DOI: 10.1038/nrneph.2010.59

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  105 in total

Review 1.  Integrins in kidney development, function, and disease.

Authors:  J A Kreidberg; J M Symons
Journal:  Am J Physiol Renal Physiol       Date:  2000-08

2.  Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis.

Authors:  Larissa Eiselein; Dennis W Wilson; Michael W Lamé; John C Rutledge
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-01-26       Impact factor: 4.733

Review 3.  Clinical review: The role of advanced glycation end products in progression and complications of diabetes.

Authors:  Su-Yen Goh; Mark E Cooper
Journal:  J Clin Endocrinol Metab       Date:  2008-01-08       Impact factor: 5.958

4.  Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes.

Authors:  Max Nieuwdorp; Hans L Mooij; Jojanneke Kroon; Bektas Atasever; Jos A E Spaan; Can Ince; Frits Holleman; Michaela Diamant; Robert J Heine; Joost B L Hoekstra; John J P Kastelein; Erik S G Stroes; Hans Vink
Journal:  Diabetes       Date:  2006-04       Impact factor: 9.461

Review 5.  RAGE and the pathogenesis of chronic kidney disease.

Authors:  Vivette D'Agati; Ann Marie Schmidt
Journal:  Nat Rev Nephrol       Date:  2010-04-27       Impact factor: 28.314

6.  Human mesangial cells express inducible macrophage scavenger receptor.

Authors:  X Z Ruan; Z Varghese; S H Powis; J F Moorhead
Journal:  Kidney Int       Date:  1999-08       Impact factor: 10.612

Review 7.  The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy.

Authors:  S Chen; S W Hong; M C Iglesias-de la Cruz; M Isono; A Casaretto; F N Ziyadeh
Journal:  Ren Fail       Date:  2001 May-Jul       Impact factor: 2.606

Review 8.  Hyperglycemia, lipoprotein glycation, and vascular disease.

Authors:  Arvindan Veiraiah
Journal:  Angiology       Date:  2005 Jul-Aug       Impact factor: 3.619

Review 9.  Albuminuria reflects widespread vascular damage. The Steno hypothesis.

Authors:  T Deckert; B Feldt-Rasmussen; K Borch-Johnsen; T Jensen; A Kofoed-Enevoldsen
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

10.  Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease.

Authors:  Samy Hakroush; Marcus J Moeller; Franziska Theilig; Brigitte Kaissling; Tjeerd P Sijmonsma; Manfred Jugold; Ann L Akeson; Milena Traykova-Brauch; Hiltraud Hosser; Brunhilde Hähnel; Hermann-Josef Gröne; Robert Koesters; Wilhelm Kriz
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

View more
  55 in total

1.  The role of vascular endothelial growth factor +405 G/C polymorphism and albuminuria in patients with type 2 diabetes mellitus.

Authors:  Abdolrahim Nikzamir; Alireza Esteghamati; Amir Abbas Hammedian; Touraj Mahmoudi
Journal:  Mol Biol Rep       Date:  2011-05-12       Impact factor: 2.316

2.  Diabetic nephropathy induces alterations in the glomerular and tubule lipid profiles.

Authors:  Kerri J Grove; Paul A Voziyan; Jeffrey M Spraggins; Suwan Wang; Paisit Paueksakon; Raymond C Harris; Billy G Hudson; Richard M Caprioli
Journal:  J Lipid Res       Date:  2014-05-26       Impact factor: 5.922

Review 3.  Obesity, metabolic syndrome and diabetic nephropathy.

Authors:  Christine Maric; John E Hall
Journal:  Contrib Nephrol       Date:  2011-06-09       Impact factor: 1.580

4.  Role of triglyceride-rich lipoproteins in renal injury.

Authors:  Kit Fai Ng; Hnin Hnin Aung; John C Rutledge
Journal:  Contrib Nephrol       Date:  2011-06-09       Impact factor: 1.580

5.  Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice.

Authors:  T Kuwabara; K Mori; M Mukoyama; M Kasahara; H Yokoi; Y Saito; Y Ogawa; H Imamaki; T Kawanishi; A Ishii; K Koga; K P Mori; Y Kato; A Sugawara; K Nakao
Journal:  Diabetologia       Date:  2012-05-19       Impact factor: 10.122

Review 6.  Obesity in kidney disease: A heavyweight opponent.

Authors:  Raphael Jose Ferreira Felizardo; Marina Burgos da Silva; Cristhiane Favero Aguiar; Niels Olsen Saraiva Câmara
Journal:  World J Nephrol       Date:  2014-08-06

7.  Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients.

Authors:  Anne Julie Overgaard; Tine E Thingholm; Martin R Larsen; Lise Tarnow; Peter Rossing; James N McGuire; Flemming Pociot
Journal:  Clin Proteomics       Date:  2010-09-10       Impact factor: 3.988

Review 8.  Treatment and impact of dyslipidemia in diabetic nephropathy.

Authors:  Tadashi Toyama; Miho Shimizu; Kengo Furuichi; Shuichi Kaneko; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2013-11-07       Impact factor: 2.801

9.  Mechanisms of bradykinin-induced expression of connective tissue growth factor and nephrin in podocytes.

Authors:  J Abou Msallem; H Chalhoub; M Al-Hariri; L Saad; M A Jaffa; F N Ziyadeh; A A Jaffa
Journal:  Am J Physiol Renal Physiol       Date:  2015-10-07

10.  Postprandial VLDL lipolysis products increase monocyte adhesion and lipid droplet formation via activation of ERK2 and NFκB.

Authors:  Laura J den Hartigh; Robin Altman; Jennifer E Norman; John C Rutledge
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-10-25       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.